Alzinova AB (ALZ) AI Stock Analysis

• Market Cap: kr158.57M
• Dividend Yield: N/A
• Average Volume (3M): 680.42K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.11
• Revenue Growth: -67.00%
• EPS Growth: 13.62%
• Country: SE
• Employees: 5
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 104,323,586
• 10 Day Avg. Volume: 666,982
• 30 Day Avg. Volume: 680,420
• PEG Ratio: 0.46
• Price to Book (P/B): 1.87
• Price to Sales (P/S): 7703.54
• P/FCF Ratio: -6.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): -3.25
• Revenue Forecast (FY): kr358.09M

• Rating: 49 Neutral
• Price Target: kr1.50 ▲(2.04% Upside)

Alzinova AB's overall stock score is primarily impacted by its financial performance, which shows significant challenges with persistent losses and negative cash flows. Technical analysis provides mixed signals, with some short-term bullish momentum but overall uncertainty. The valuation is unattractive due to negative profitability metrics. The absence of earnings call data and corporate events means these factors do not influence the score.

Alzinova AB Business Overview & Revenue Model

Company Description

Alzinova AB (ALZ) is a biotechnology company focused on developing innovative immunotherapy-based solutions for the treatment of Alzheimer's disease. The company operates within the healthcare sector, primarily concentrating on the discovery and development of novel therapeutic candidates aimed at targeting harmful amyloid-beta aggregates that are implicated in Alzheimer's pathology. Alzinova's core product is its proprietary drug candidates, including ALZ-101, which is in clinical development stages.

How the Company Makes Money

Alzinova AB generates revenue primarily through the advancement of its drug candidates, including potential milestone payments from partnerships and collaborations with larger pharmaceutical companies. The company may also earn revenue from licensing agreements, where it grants rights to its intellectual property or technology in exchange for upfront payments and royalties on future sales. As the company progresses through clinical trials and approaches potential regulatory approvals, it stands to benefit from increased investments and partnerships, which can further enhance its revenue streams.

Alzinova AB Financial Statement Overview

Summary

Alzinova AB faces substantial financial challenges with persistent losses and negative cash flows, despite strong equity and no debt. The biotechnology industry often involves high R&D costs, which may contribute to these financial results. While the company's equity position offers some stability, its path to profitability remains uncertain, requiring strategic focus on improving revenue and controlling expenses.

Income Statement

Alzinova AB's revenue has seen significant fluctuations, with a notable decline from 2022 to 2023. The company operates with negative profit margins, including a net profit margin of -685% in 2023, indicating substantial losses relative to revenue. The consistent negative EBIT and EBITDA margins reflect ongoing operational challenges. However, the company has maintained a relatively stable gross profit margin, suggesting some efficiency in managing direct costs.

Balance Sheet

The balance sheet shows a strong equity position with zero total debt in the latest period, reducing financial risk. The equity ratio improved to 93%, indicating a solid foundation with minimal liabilities. However, the company has a negative return on equity due to consistent net losses, which may concern investors seeking profitability.

Cash Flow

Cash flow analysis reveals significant free cash flow deficits, worsening from 2022 to 2023, driven by negative operating cash flow. The free cash flow to net income ratio is negative, highlighting cash flow challenges in covering net losses. Moreover, the reliance on financing activities to support cash reserves may not be sustainable in the long run.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	99.00K	30.00K	270.00K	16.63M	17.32M	14.90M
Gross Profit	25.78M	16.81M	19.87M	33.27M	34.64M	29.80M
EBITDA	-23.78M	-20.32M	42.00K	-13.07M	-7.52M	-6.50M
Net Income	-24.07M	-20.55M	-16.48M	-13.07M	-7.58M	-6.50M
Balance Sheet
Total Assets	143.69M	133.23M	123.19M	111.62M	91.69M	100.82M
Cash, Cash Equivalents and Short-Term Investments	11.51M	15.50M	22.03M	32.04M	28.84M	55.98M
Total Debt	0.00	800.00K	800.00K	800.00K	800.00K	800.00K
Total Liabilities	8.87M	9.40M	9.33M	6.09M	3.22M	4.79M
Stockholders Equity	134.82M	123.82M	113.86M	105.53M	88.47M	96.02M
Cash Flow
Free Cash Flow	-42.41M	-37.05M	-34.82M	-26.95M	-27.14M	-21.17M
Operating Cash Flow	-22.73M	-20.27M	-15.21M	-10.31M	-9.82M	-6.27M
Investing Cash Flow	-25.68M	-16.78M	-19.60M	-16.63M	-17.32M	-14.90M
Financing Cash Flow	54.93M	30.52M	24.80M	30.15M	0.00	43.41M

Alzinova AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.47
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALZ, the sentiment is Positive. The current price of 1.47 is above the 20-day moving average (MA) of 1.45, above the 50-day MA of 1.42, and below the 200-day MA of 1.82, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.08 is Neutral, neither overbought nor oversold. The STOCH value of 52.45 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ALZ.

Alzinova AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALZ	49 Neutral	kr158.57M	―	-20.85%	―	-67.00%	13.62%
NXTCL	47 Neutral	kr81.87M	―	-52.45%	―	2.56%	52.76%
MODTX	42 Neutral	€47.80M	-2.16	-1117.29%	―	―	21.80%
BIOVIC.B	39 Underperform	€141.00M	-0.70	-146.43%	―	31.03%	55.25%
NICA	38 Underperform	€114.42M	-2.27	-294.38%	―	186.74%	73.17%
BIOSGN	34 Underperform	kr112.48M	―	-201.21%	―	―	49.10%